Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):513-515. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2023.0044

View: 633 Download: 26

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 709 Download: 37

Review

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 1425 Download: 173 Citation: 1

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(2):252-262. Published online March 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0099

View: 1210 Download: 132

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 2438 Download: 179 Citations: 6

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 2903 Download: 150 Citations: 9

Review

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

View: 3210 Download: 200 Citations: 8

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 6859 Download: 464 Citations: 22

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 3192 Download: 240 Citations: 8

Editorial

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 3928 Download: 103 Citation: 1

Review

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 21715 Download: 617 Citations: 126

Case Report

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B

Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang

Clin Mol Hepatol. 2018;24(4):430-435. Published online November 27, 2017

DOI: https://doi.org/10.3350/cmh.2017.0016

View: 7072 Download: 215 Citations: 2

Original Article

Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases

San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón

Clin Mol Hepatol. 2018;24(4):384-391. Published online July 4, 2018

DOI: https://doi.org/10.3350/cmh.2018.0004

View: 6818 Download: 191 Citations: 9

Review

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong

Clin Mol Hepatol. 2018;24(2):108-113. Published online January 22, 2018

DOI: https://doi.org/10.3350/cmh.2017.0068

View: 11399 Download: 489 Citations: 34

Editorial

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

View: 5286 Download: 137

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 8447 Download: 160 Citations: 13

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 6929 Download: 149 Citations: 2

Original Article

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik

Clin Mol Hepatol. 2017;23(2):170-178. Published online May 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0086

View: 8317 Download: 206 Citations: 34

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2017;23(2):154-159. Published online May 8, 2017

DOI: https://doi.org/10.3350/cmh.2016.0067

View: 6700 Download: 170 Citations: 7

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol. 2016;22(4):458-465. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0054

View: 7890 Download: 129 Citations: 7

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol. 2016;22(4):443-449. Published online November 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0037

View: 8816 Download: 155 Citations: 7

Editorial

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 6827 Download: 109

Review

New perspectives of biomarkers for the management of chronic hepatitis B

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2016;22(4):423-431. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0069

View: 11784 Download: 525 Citations: 40

Original Article

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment

Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi

Clin Mol Hepatol. 2016;22(3):350-358. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0019

View: 7954 Download: 132 Citation: 1

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park

Clin Mol Hepatol. 2016;22(3):339-349. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0021

View: 10518 Download: 155 Citations: 18

Editorial

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol. 2016;22(3):336-338. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0104

View: 7107 Download: 110 Citation: 1

Case Report

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases

Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2016;22(2):286-291. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2015.0066

View: 9058 Download: 168 Citations: 13

Original Article

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy

Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon

Clin Mol Hepatol. 2016;22(2):241-249. Published online June 15, 2016

DOI: https://doi.org/10.3350/cmh.2015.0053

View: 8994 Download: 134 Citations: 4

Editorial

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 7615 Download: 92 Citation: 1

Original Article

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park

Clin Mol Hepatol. 2016;22(1):152-159. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.152

View: 8661 Download: 93

1 | 2 | 3 |

Viewed By 4126	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2723	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2445	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Viewed By 2437	Management of refractory ascites
Viewed By 2436	Recent updates on the management of autoimmune hepatitis

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 43	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search